Search research articles
Contact Us
Filters
Showing results (471-480 of 501) with videos related to
Page
of 51
Sort By:
Nature Cancer
|
March 18, 2025
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Won Seog Kim, Tae Min Kim, Seok-Goo Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2024
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Francine M Foss, Youn H Kim, H Miles Prince, et al.
Internal Medicine Journal
|
October 19, 2021
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia
Katherine Creeper, Bradley Augustson, Kieran Kusel, et al.
Blood
|
August 16, 2011
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
Werner Kempf, Katrin Pfaltz, Maarten H Vermeer, et al.
Blood
|
December 29, 2025
Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
Jeremy S Abramson, David J Straus, Nancy L Bartlett, et al.
Blood
|
December 5, 2025
Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium
Mark N Sorial, Luis Malpica, Carlos Sergio Chiattone, et al.
British Journal of Haematology
|
April 21, 2015
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data
Susan E Bates, Robin Eisch, Alexander Ling, et al.
Blood Advances
|
September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data
Steven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.
Leukemia & Lymphoma
|
August 20, 2025
Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy
Elżbieta Iskierka-Jażdżewska, Won Seog Kim, Seok-Goo Cho, et al.
Journal of Medicinal Chemistry
|
July 3, 2020
Discovery of AB680: A Potent and Selective Inhibitor of CD73
Kenneth V Lawson, Jaroslaw Kalisiak, Erick A Lindsey, et al.
Page
of 51
Search research articles
Search
Showing results (471-480 of 501) with videos related to
Sort By:
Page
of 51
Nature Cancer
|
March 18, 2025
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Won Seog Kim, Tae Min Kim, Seok-Goo Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2024
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Francine M Foss, Youn H Kim, H Miles Prince, et al.
Internal Medicine Journal
|
October 19, 2021
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia
Katherine Creeper, Bradley Augustson, Kieran Kusel, et al.
Blood
|
August 16, 2011
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
Werner Kempf, Katrin Pfaltz, Maarten H Vermeer, et al.
Blood
|
December 29, 2025
Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
Jeremy S Abramson, David J Straus, Nancy L Bartlett, et al.
Blood
|
December 5, 2025
Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium
Mark N Sorial, Luis Malpica, Carlos Sergio Chiattone, et al.
British Journal of Haematology
|
April 21, 2015
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data
Susan E Bates, Robin Eisch, Alexander Ling, et al.
Blood Advances
|
September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data
Steven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.
Leukemia & Lymphoma
|
August 20, 2025
Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy
Elżbieta Iskierka-Jażdżewska, Won Seog Kim, Seok-Goo Cho, et al.
Journal of Medicinal Chemistry
|
July 3, 2020
Discovery of AB680: A Potent and Selective Inhibitor of CD73
Kenneth V Lawson, Jaroslaw Kalisiak, Erick A Lindsey, et al.
Page
of 51